Scopus BioPharma Debt/Equity Ratio 2020-2023 | SCPS

Scopus BioPharma debt/equity ratio from 2020 to 2023. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

Scopus BioPharma Debt/Equity Ratio 2020-2023 | SCPS

Scopus BioPharma debt/equity ratio from 2020 to 2023. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$169.8B
Vertex Pharmaceuticals (VRTX)$121.4B
Gilead Sciences (GILD)$109.7B
Bristol Myers Squibb (BMY)$106.4B
Regeneron Pharmaceuticals (REGN)$102.2B
CSL (CSLLY)$92.8B
GSK (GSK)$79.1B
Alnylam Pharmaceuticals (ALNY)$36.5B
Argenex SE (ARGX)$33.1B
BioNTech SE (BNTX)$27.1B
Biogen (BIIB)$26.7B
Illumina (ILMN)$23.3B
Moderna (MRNA)$21.2B
BeiGene (BGNE)$21.1B
Genmab (GMAB)$15.3B
Incyte (INCY)$14.2B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$12.9B
Sarepta Therapeutics (SRPT)$12.4B
Insmed (INSM)$12.2B
Vaxcyte (PCVX)$11.8B
Bio-Techne Corp (TECH)$11.2B
QIAGEN (QGEN)$9.5B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.6B
Revolution Medicines (RVMD)$8.4B
Legend Biotech (LEGN)$8.3B
Exelixis (EXEL)$8.2B
Viking Therapeutics (VKTX)$8.2B
Intra-Cellular Therapies (ITCI)$8.1B